Clinical study on Yixiao Decoction in the treatment of type 2 diabetes complicated with left ventricular diastolic dysfunction

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045193

Enrollment

Unknown

Registered

2021-04-08

Start date

2021-04-10

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Yixiao Decoction group:Basic therapy+Yixiao Decoction

Control group:Basic therapy

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged >40 and <75 years; 2.Meet the diagnosis of type 2 diabetes; 3.Meet the diagnosis of left ventricular diastolic dysfunction; 4.Meet the TCM diagnosis of Qi and yin deficiency and blood stasis syndrome; 5.Patients who are able to correctly describe their wishes, voluntarily fill in the informed consent form and agree to participate in clinical trials.

Exclusion criteria

Exclusion criteria: 1.Left ventricular ejection fraction < 50%; 2.Patients with type 1 diabetes and other types of diabetes; 3.Patients with rheumatic valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy and other heart diseases have been definitely diagnosed; 4.Patients with acute or severe complications of diabetes, such as ketoacidosis, hyperosmolar coma, infection, etc; 5.Patients with chronic wasting diseases such as immune system diseases and malignant tumors; 6.Patients with severe renal failure, liver coma and other visceral dysfunction, renal insufficiency requiring hemodialysis; 7.Patients with severe electrolyte disorder and hematopathy; 8.Patients with various mental diseases; 9.Pregnant or lactating women, and women planning pregnancy or without contraception plan; 10.Patients with diabetic retinopathy (proliferative stage) and hemorrhagic diseases; 11.Patients known or suspected to be allergic to the drugs used in this study; 12.Participants in other clinical trials within 3 months.

Design outcomes

Primary

Measure	Time frame
Echocardiography;Fasting blood glucose;2h postprandial blood glucose;Glycated Albumin;Glycosylated hemoglobin;	—

Secondary

Measure	Time frame
Urine acetone bodies;Uric acid;Transforming growth factor-ß1;Connective tissue growth factor;Carboxyterminal of type I procollagen;Procollagen III N-termi;	—

Countries

China

Contacts

Public ContactYang Xiaohui

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

yxh0616@126.com+86 10 84013183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026